Penile cancer
ICD-10 C60 · ICD-11 2C81

Treatment of Distant Metastatic Penile Squamous Cell Carcinoma (M1)

When penile squamous cell carcinoma has spread to distant sites — classified as M1 disease — systemic palliative therapy becomes the central treatment strategy. This page outlines the clinical scenario and provides a partial overview of the evidence-based approach.

Clinical Scenario

Distant metastatic penile squamous cell carcinoma (M1) encompasses disease that has disseminated beyond regional lymph nodes to distant organs or sites. At this stage, curative intent is not feasible, and the clinical focus shifts to palliative systemic control. Guidelines recommend platinum-based chemotherapy as the preferred approach to first-line palliative systemic therapy in this population.

Treatment Approach (Partial Summary)

First-line palliative treatment centres on platinum-based chemotherapy, with both combination and single-agent options available depending on patient suitability and performance status. Certain agents are specifically excluded from consideration in this setting because of unacceptable toxicity risk.

The complete regimen — including all options, selection criteria, and contraindications — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

  1. Offer patients with distant metastatic disease platinum-based chemotherapy as the preferred approach to first-line palliative systemic therapy.
  2. Do not offer bleomycin due to the pulmonary toxicity risk.
  3. These data support the recommendation of platinum-based chemotherapy as the preferred approach to first-line palliative systemic therapy.
View source ↗